Providence, RINCT06974604Now EnrollingIRB Ready

Breast Neoplasms Clinical Trial in Providence, RI

Access cutting-edge breast neoplasms treatment through this phase 2 clinical trial at a research site in Providence. Study-provided care at no cost to qualified participants.

Sponsored by Brown University

Quick Self-Assessment

See if you qualify for this Providence location

Preparing your pre-screening questions…

Expert Care in Providence

Access breast neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast neoplasms treatment provided free

Apply for This Providence Location

Check if you qualify for this breast neoplasms clinical trial in Providence, RI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Providence

    Convenient for RI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Providence site if eligible
  4. 4Begin participation

About This Breast Neoplasms Study in Providence

TROPION-DM/BrUOG-431 is a prospective, , phase 2 trial with two non-comparative cohorts analyzed jointly for primary endpoint in adult patients with either (Cohort 1:) advanced/metastatic hormone-receptor positive (\[HR+\], estrogen receptor and/or progesterone receptor positive) breast cancer (BC), or advanced/metastatic triple negative breast cancer (TNBC) or (Cohort 2:) advanced/metastatic non-squamous non-small cell lung cancer (NSCLC). All patients will be treated with Datopotumab deruxtecan (Dato-DXd) at 6 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity. Due to the risk of stomatitis, the investigational component of this trial will be to incorporate alcohol-free dexamethasone mouthwash, 10 mL 0.5 mg/5mL oral solution, days 1-5, swish and spit four times daily for the first 3 cycles.

Sponsor: Brown University

Who Can Participate

Inclusion Criteria

Has advanced and/or metastatic cancer that meets one of the following criteria:
Pathologically documented unresectable advanced non-squamous NSCLC not amenable to curative therapy that has progressed on at least one prior therapy.
Pathologically documented triple negative breast cancer (estrogen receptor negative and progesterone receptor negative and HER2 negative) who have progressed on at least 1 prior line of therapy or in the opinion of the treating physician, not be a candidate for standard first-line metastatic breast cancer therapy
Pathologically documented hormone receptor positive breast cancer (estrogen receptor and/or progesterone receptor positive, HER2 negative) which has progressed on hormonal based therapy including CDK4/6 inhibitor and 1 prior line of chemotherapy and/or antibody drug conjugate therapy.
Aged ≥18 years.
Has an Eastern Cooperative Oncology Group performance status 0-2.
Has a left ventricular ejection fraction (LVEF) 50% by either an echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 28 days before enrollment.
Measurable disease based on Response Evaluation Criteria in Solids Tumors (RECIST) version 1.1.
Has adequate organ function that would make them an appropriate candidate for Datopotamab deruxtecan therapy as treatment of advanced metastatic cancer as assessed by the treating physician, which shall include results of complete blood count with differential, and comprehensive metabolic panel within 14 days before Cycle 1, Day 1, defined as:
Platelet count ≥100,000/mm3
Hemoglobin ≥9.0 g/dL
Absolute neutrophil count ≥1000/mm3
Creatinine clearance ≥30 mL/min as calculated using the Cockcroft-Gault equation.
Aspartate aminotransferase ≤3 ×ULN (if liver metastases are present, ≤5 × ULN)
Alanine aminotransferase ≤3 × ULN (if liver metastases are present, ≤5 × ULN)
Total bilirubin ≤1.5 × ULN if no liver metastases or liver \< 3 if liver metastases are present.
Has an adequate treatment washout period prior to Cycle 1, Day 1, defined as appropriately recovering from:
Major surgery: ≥2 weeks (or 2 weeks for low-invasive cases \[eg, colostomy\]).
Radiation therapy (curative) and palliative radiation therapy to lung fields: ≥4 weeks; ≥2 weeks (palliative radiation therapy to other areas \[ie, limited field and 10 or fewer days or fractions\] including whole brain radiotherapy).
Hormonal therapy: ≥2 weeks
Chemotherapy (including immunotherapy \[non-antibody based therapy\]), and retinoid therapy: ≥2 weeks or 5 times terminal elimination half-life (T½) of the chemotherapeutic agent (whichever is longer); ≥6 weeks for nitrosoureas or mitomycin C, ≥1 week for tyrosine kinase inhibitors (TKIs)
Antibody-based anti-cancer therapy: ≥4 weeks
Chloroquine/hydroxychloroquine: \>14 days
If of reproductive/child-bearing potential, agrees to use a highly effective form of contraception or avoid intercourse throughout treatment and upon completion of the study for at least 7 months for females and 4 months for males after the last dose of study drug. Highly effective methods of birth control include: combined (estrogen and progesterone containing) hormonal contraception by oral or intravaginal route or dermal patches; progesterone-only hormonal contraception associated with inhibition of ovulation given by oral route or by injections or implants; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner (with confirmation of surgical success); and complete heterosexual abstinence.
Starting at the time of randomization/first dose of study intervention male subjects/participants must not freeze or donate sperm at any time during this study and for at least 4 months after the last dose of Dato-DXd. Preservation of sperm should be considered prior to randomization/first dose of study intervention.
Starting at the time of randomization/first dose of study intervention female subjects/participants must not breastfeed or donate, or retrieve for their own use, ova at any time during this study and for at least 7 months after the last dose of Dato-DXd. Preservation of ova should be considered prior to randomization/first dose of study intervention.
Is able to provide written informed consent and is willing and able to comply with the protocol. Subject must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible toxicities) and must sign and date the Institutional Review Board (IRB)/Independent ethics committee (IEC) approved informed consent form (ICF) (including Health Insurance Portability and Accountability Act authorization \[HIPAA\], if applicable) before performance of any study- specific procedures or examinations.
Willingness to self-report level of oral pain using Visual Analog Scale (VAS) and the Normalcy Diet Scale (NDS) throughout each stomatitis event. (40, 41) At baseline, patient's self-reported oral pain level, using VAS, must be 0 (See Appendix B) and the normalcy diet scale score should ≥ 60 (See Appendix C).
Willingness to record oral symptoms in Oral Diary (See Appendix D).
Has a life expectancy of ≥3 months.

Exclusion Criteria

Active second malignancy which would alter interpretation of study results.
Has a history of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
Has clinically significant corneal disease
Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients (including but not limited to polysorbate 80) of Dato-DXd.
Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
Has ongoing radiation-related toxicities
Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
Has active human immunodeficiency virus (HIV) infection that is not well controlled.
Has an active or uncontrolled hepatitis B and/or hepatitis C infection
Is lactating or pregnant as confirmed by pregnancy tests performed within 7 days before enrollment.
Clinically severe pulmonary compromise resulting from autoimmune, connective tissue or inflammatory disorders with pulmonary involvement.
Has uncontrolled or significant cardiac disease (including MI or unstable angina within the past 6 months, NYHA Class II-IV heart failure, uncontrolled hypertension, uncontrolled or significant arrhythmia). Patients with the following may be enrolled based on the investigator's/treating physician's assessment (documentation must be submitted to BrUOG). -Mean resting corrected QTcF interval \> 470 ms.
History of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause Torsades de Pointes.
Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Providence?

Yes, this clinical trial (NCT06974604) has an active research site in Providence, RI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Neoplasms Treatment Options in Providence, RI

If you're searching for breast neoplasms treatment options in Providence, RI, this clinical trial (NCT06974604) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Providence research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced breast neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast neoplasms clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Providence, RI

See all breast cancer clinical trials recruiting in Providence — not just this study.

Browse Breast Cancer Trials in Providence →

Browse More Trials by Condition

Breast Cancer TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Providence?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Providence, RI